Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II single-arm study of tocilizumab for cancer-associated inflammatory cachexia
ChiCTR2400080103Phase 2Recruiting
- Sponsor
- Peking Union Medical College Hospital
- Start
- Jan 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tocilizumab in cancer anorexia-cachexia syndrome (CACS), sponsored by Peking Union Medical College Hospital. Primary endpoint: Survival and modified Glasgow Prognostic Score improvement at Week 16. Started Jan 2024; status: recruiting.
02
Drugs
tocilizumab
03
Conditions
cancer anorexia-cachexia syndrome (CACS)
Beyond the preview
Go deeper on ChiCTR2400080103.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400080103.